Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic ...
The article reports on the first-in-human phase I trial, BrainChild-03, using B7-H3-specific CAR T cells for treating recurrent/refractory CNS tumors and DIPG in children. It highlights preclinical efficacy, clinical tolerability, and evidence of local immune activation and persistent CAR T cells in the CSF. The study suggests the feasibility of repeated intracranial B7-H3 CAR T-cell dosing, with one patient showing sustained improvement over 12 months.
Related Clinical Trials
Reference News
The article reports on the first-in-human phase I trial, BrainChild-03, using B7-H3-specific CAR T cells for treating recurrent/refractory CNS tumors and DIPG in children. It highlights preclinical efficacy, clinical tolerability, and evidence of local immune activation and persistent CAR T cells in the CSF. The study suggests the feasibility of repeated intracranial B7-H3 CAR T-cell dosing, with one patient showing sustained improvement over 12 months.